Medite Cancer Diagnostics, Inc. (MDIT)

Market Cap	8.58K -99.8%
Revenue (ttm)	8.13M +19.5%
Net Income	-5.42M
EPS	-0.11
Shares Out	85.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	380
Average Volume	6,044
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0050
Beta	508.62
RSI	44.65
Earnings Date	n/a

About Medite Cancer Diagnostics

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue s...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Employees: 69
• Stock Exchange: OTCMKTS
• Ticker Symbol: MDIT

Financial Performance

In 2017, Medite Cancer Diagnostics's revenue was $6.81 million, a decrease of -26.25% compared to the previous year's $9.24 million. Losses were -$6.90 million, 206.2% more than in 2016.